AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 264 min read$PAHC

PHIBRO ANIMAL HEALTH CORP (PAHC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

PHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001069899 0001069899 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report

Original reporting
SEC EDGAR 8-K
Published Jun 26, 2026, 9:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 26, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$PAHC
Neutral
medium confidence
Mentioned
$PAHC
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PAHCNeutralMed
01

Why it matters

The disclosure provides concrete incentive terms (base salary, bonus eligibility, and RSU vesting thresholds based on a 90-day average of PAHC’s closing price) that can influence how investors model management alignment and risk-taking.

02

Market read

This is a primary-source executive transition filing with specific equity-vesting conditions tied to PAHC’s stock-price range, which can drive short-term sentiment and positioning.

03

What to watch

Traders may over-weight the compensation headline; the more important catalysts will be any subsequent strategic updates, guidance, or operational performance under the new CEO.

Relevance 6/10Novelty 6/10Timing: ahead of the July 1, 2026 CEO effective date

Background

The 8-K (Item 5.02) reports the board’s approval of an employment agreement and a performance-based RSU award for incoming CEO Dani Bendheim effective July 1, 2026.

Company-level read

Ticker impact

$PAHCNeutralMedium confidence
Context

Phibro Animal Health disclosed CEO Dani Bendheim’s July 1 start and a performance-vested RSU grant tied to a $70–$100 stock-price range.

Expected impact

Likely modest, sentiment-driven reaction around the appointment/compensation terms; follow-through depends on subsequent guidance and performance.

Evidence & confidence

The filing is a primary-source 8-K with concrete compensation/vesting thresholds, but it does not include earnings, guidance, or operational milestones.

Market effects

Sector

Limited read-across to animal health peers; this is company-specific leadership and incentive design.

Regional

No clear regional spillover beyond Nasdaq-listed small/mid-cap sentiment.

Global

No direct global macro or cross-border transaction disclosed.

Counterpoint

What could challenge this read

The RSU vesting is contingent on a long-dated stock-price average (through 2031), so the near-term trading impact may fade quickly.

Key entities

  • company
    Phibro Animal Health Corporation

    Nasdaq-listed animal health company; disclosed CEO appointment and compensation/RSU vesting mechanics in an 8-K.

  • executive
    Daniel (Dani) Bendheim

    Appointed Chief Executive Officer and President effective July 1, 2026; received 300,000 performance-based RSUs.

  • board
    Compensation Committee of the Board of Directors

    Approved the employment agreement and RSU grant as part of the CEO transition.

Read at source← All news

Related articles

SEP 5
$PAHCMedAI 8/10

Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain?

Phibro Animal Health (PAHC) issued 2027 guidance, projecting net sales of $1.55b-$1.60b and net income of $122m-$132m. The company reported 2026 sales of $1.518b and net income of $99.72m. Analysts' price targets range from $38 to $58, with a consensus of $45.60, suggesting a 16.1% undervaluation. The stock has seen a 90-day return of 17.95% and a 3-year return above 200%.

yahoo.com3 min
SEP 1
$PAHCHighAI 8/10

Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year

Phibro Animal Health (PAHC) reported fiscal 2026 net sales of $1.5B, adjusted EBITDA up 39% to $255M, and EPS up 48% to $3.22. The growth was driven by a recent acquisition and organic growth across segments. Guidance for fiscal 2027 expects slower growth with net sales of $1.55B-$1.6B and EBITDA of $258M-$268M. Free cash flow was $9.9M due to inventory buildup, with debt at $737.9M and a leverage ratio of 2.9x EBITDA.

yahoo.com3 min
AUG 31
$PAHCHighAI 8/10

Phibro (PAHC) Q4 2026 Earnings Call Transcript

Phibro (PAHC) reported Q4 2026 net sales of $396.7M, up 5%, and adjusted EBITDA of $255M, up 39% YoY. Full-year sales reached $1.518B, up 17%, with adjusted EBITDA up 39%. CEO Dani Bendheim highlighted strong performance across segments, including a 20% increase in Mineral Nutrition sales. The company provided fiscal 2027 guidance, expecting net sales of $1.55B-$1.6B and adjusted EBITDA of $258M-$268M. Phibro also announced the closure of a Chicago facility and discussed regulatory uncertainties

yahoo.com2 min
AUG 27
$PAHCHighAI 8/10

Phibro Animal Health Q4 Earnings Call Highlights

Phibro Animal Health (PAHC) reported Q4 and full-year 2026 results, with legacy MFA and other revenue up 4%, Nutritional Specialties up 9%, and vaccine revenue up 14%. The company expects fiscal 2027 sales of $1.55B-$1.60B and adjusted EBITDA of $258M-$268M, with growth driven by acquired MFA products and international demand. However, Brazil regulatory uncertainty and higher input costs may impact performance. Phibro also plans to close its Chicago Heights facility, expecting $15M-$20M in annua

yahoo.com2 min
AUG 26
$PAHCHigh

PHIBRO ANIMAL HEALTH CORP (PAHC): Results of Operations and Financial Condition

PHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ For Immediate Release ​ Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance ​ TEANECK, N.J., August 26, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) tod

SEC EDGAR 8-K2 min